The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Cardiovascular diseases are leading cause of morbidity and mortality globally. Biomarkers are generally used as an indicator forparticular diseases such as rheumatic and congenital heart diseases and cardiac arrhythmia. Cardiac biomarkers are measurable and quantifiable biological parameters.
These are specifically used to check the presence or severity of cardiovascular diseases. Cardiac biomarkers are the substances that are released into blood when heart is damaged. These biomarkers are also used for diagnosing and monitoring diseases such as coronary syndrome or cardiac ischemia. The symptoms of these diseases includes chest pain, shortness of breath and nausea that ultimately leads to heart attack or angina. Cardiac biomarker tests helps to detect presence of coronary syndrome and cardiac ischemia to evaluate its severity and diagnosis.
The global Cardiac Biomarkers market was valued at US$ 704.2 million in 2023 and is anticipated to reach US$ 1315.7 million by 2030, witnessing a CAGR of 9.2% during the forecast period 2024-2030.
The prevention of cardiac diseases by monitoring the heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment. Cardiac biomarkers are protein-based traceable substances used as an indicator of biologic state and used for diagnostic and prognostic purposes associated with heart. Cardiac biomarkers are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infraction, congestive heart failure, acute coronary syndrome (ACS) among others. The cardiac biomarkers that are widely used as an integrated diagnostic approach for CVDs include CK-MB, troponin I and T, myoglobin, BNPs, IMA and few others. Cardiac biomarkers market has witnessed a greater demand over the past five to six years.
This report aims to provide a comprehensive presentation of the global market for Cardiac Biomarkers, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cardiac Biomarkers.
Report Scope
The Cardiac Biomarkers market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cardiac Biomarkers market comprehensively.
Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cardiac Biomarkers companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
- Abbott
- F. Hoffmann-La Roche
- Advanced ImmunoChemical
- AgPlus Diagnostics
- BG Medicine
- BioLegend
- bioMérieux
- Bio-Rad Laboratories
- BODITECH MED
Segment by Type
- Troponin
- CK-MB
- Natriuretic Peptides - BNP and NT-proBNP
- Myoglobin
- Others
Segment by Application
- Acute Coronary Syndrome
- Myocardial Infarction
- Congestive Heart Failure
- Others
By Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Netherlands)
- Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
- Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cardiac Biomarkers companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cardiac Biomarkers Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Troponin
1.2.3 CK-MB
1.2.4 Natriuretic Peptides - BNP and NT-proBNP
1.2.5 Myoglobin
1.2.6 Others
1.3 Market by Application
1.3.1 Global Cardiac Biomarkers Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Acute Coronary Syndrome
1.3.3 Myocardial Infarction
1.3.4 Congestive Heart Failure
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cardiac Biomarkers Market Perspective (2019-2030)
2.2 Cardiac Biomarkers Growth Trends by Region
2.2.1 Global Cardiac Biomarkers Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Cardiac Biomarkers Historic Market Size by Region (2019-2024)
2.2.3 Cardiac Biomarkers Forecasted Market Size by Region (2025-2030)
2.3 Cardiac Biomarkers Market Dynamics
2.3.1 Cardiac Biomarkers Industry Trends
2.3.2 Cardiac Biomarkers Market Drivers
2.3.3 Cardiac Biomarkers Market Challenges
2.3.4 Cardiac Biomarkers Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cardiac Biomarkers Players by Revenue
3.1.1 Global Top Cardiac Biomarkers Players by Revenue (2019-2024)
3.1.2 Global Cardiac Biomarkers Revenue Market Share by Players (2019-2024)
3.2 Global Cardiac Biomarkers Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cardiac Biomarkers Revenue
3.4 Global Cardiac Biomarkers Market Concentration Ratio
3.4.1 Global Cardiac Biomarkers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cardiac Biomarkers Revenue in 2023
3.5 Cardiac Biomarkers Key Players Head office and Area Served
3.6 Key Players Cardiac Biomarkers Product Solution and Service
3.7 Date of Enter into Cardiac Biomarkers Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cardiac Biomarkers Breakdown Data by Type
4.1 Global Cardiac Biomarkers Historic Market Size by Type (2019-2024)
4.2 Global Cardiac Biomarkers Forecasted Market Size by Type (2025-2030)
5 Cardiac Biomarkers Breakdown Data by Application
5.1 Global Cardiac Biomarkers Historic Market Size by Application (2019-2024)
5.2 Global Cardiac Biomarkers Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Cardiac Biomarkers Market Size (2019-2030)
6.2 North America Cardiac Biomarkers Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Cardiac Biomarkers Market Size by Country (2019-2024)
6.4 North America Cardiac Biomarkers Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cardiac Biomarkers Market Size (2019-2030)
7.2 Europe Cardiac Biomarkers Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Cardiac Biomarkers Market Size by Country (2019-2024)
7.4 Europe Cardiac Biomarkers Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cardiac Biomarkers Market Size (2019-2030)
8.2 Asia-Pacific Cardiac Biomarkers Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Cardiac Biomarkers Market Size by Region (2019-2024)
8.4 Asia-Pacific Cardiac Biomarkers Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cardiac Biomarkers Market Size (2019-2030)
9.2 Latin America Cardiac Biomarkers Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Cardiac Biomarkers Market Size by Country (2019-2024)
9.4 Latin America Cardiac Biomarkers Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cardiac Biomarkers Market Size (2019-2030)
10.2 Middle East & Africa Cardiac Biomarkers Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Cardiac Biomarkers Market Size by Country (2019-2024)
10.4 Middle East & Africa Cardiac Biomarkers Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott
11.1.1 Abbott Company Detail
11.1.2 Abbott Business Overview
11.1.3 Abbott Cardiac Biomarkers Introduction
11.1.4 Abbott Revenue in Cardiac Biomarkers Business (2019-2024)
11.1.5 Abbott Recent Development
11.2 Abbott
11.2.1 Abbott Company Detail
11.2.2 Abbott Business Overview
11.2.3 Abbott Cardiac Biomarkers Introduction
11.2.4 Abbott Revenue in Cardiac Biomarkers Business (2019-2024)
11.2.5 Abbott Recent Development
11.3 F. Hoffmann-La Roche
11.3.1 F. Hoffmann-La Roche Company Detail
11.3.2 F. Hoffmann-La Roche Business Overview
11.3.3 F. Hoffmann-La Roche Cardiac Biomarkers Introduction
11.3.4 F. Hoffmann-La Roche Revenue in Cardiac Biomarkers Business (2019-2024)
11.3.5 F. Hoffmann-La Roche Recent Development
11.4 Advanced ImmunoChemical
11.4.1 Advanced ImmunoChemical Company Detail
11.4.2 Advanced ImmunoChemical Business Overview
11.4.3 Advanced ImmunoChemical Cardiac Biomarkers Introduction
11.4.4 Advanced ImmunoChemical Revenue in Cardiac Biomarkers Business (2019-2024)
11.4.5 Advanced ImmunoChemical Recent Development
11.5 AgPlus Diagnostics
11.5.1 AgPlus Diagnostics Company Detail
11.5.2 AgPlus Diagnostics Business Overview
11.5.3 AgPlus Diagnostics Cardiac Biomarkers Introduction
11.5.4 AgPlus Diagnostics Revenue in Cardiac Biomarkers Business (2019-2024)
11.5.5 AgPlus Diagnostics Recent Development
11.6 BG Medicine
11.6.1 BG Medicine Company Detail
11.6.2 BG Medicine Business Overview
11.6.3 BG Medicine Cardiac Biomarkers Introduction
11.6.4 BG Medicine Revenue in Cardiac Biomarkers Business (2019-2024)
11.6.5 BG Medicine Recent Development
11.7 BioLegend
11.7.1 BioLegend Company Detail
11.7.2 BioLegend Business Overview
11.7.3 BioLegend Cardiac Biomarkers Introduction
11.7.4 BioLegend Revenue in Cardiac Biomarkers Business (2019-2024)
11.7.5 BioLegend Recent Development
11.8 bioMérieux
11.8.1 bioMérieux Company Detail
11.8.2 bioMérieux Business Overview
11.8.3 bioMérieux Cardiac Biomarkers Introduction
11.8.4 bioMérieux Revenue in Cardiac Biomarkers Business (2019-2024)
11.8.5 bioMérieux Recent Development
11.9 Bio-Rad Laboratories
11.9.1 Bio-Rad Laboratories Company Detail
11.9.2 Bio-Rad Laboratories Business Overview
11.9.3 Bio-Rad Laboratories Cardiac Biomarkers Introduction
11.9.4 Bio-Rad Laboratories Revenue in Cardiac Biomarkers Business (2019-2024)
11.9.5 Bio-Rad Laboratories Recent Development
11.10 BODITECH MED
11.10.1 BODITECH MED Company Detail
11.10.2 BODITECH MED Business Overview
11.10.3 BODITECH MED Cardiac Biomarkers Introduction
11.10.4 BODITECH MED Revenue in Cardiac Biomarkers Business (2019-2024)
11.10.5 BODITECH MED Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
